Objective response rate assessment in oncology: Current situation and future expectations

被引:43
|
作者
Aykan, Nuri Faruk [1 ]
Ozatli, Tahsin [1 ]
机构
[1] Istinye Univ, Bahcesehir Liv Hosp, Med Sch, Dept Med Oncol, Ataturk Bulvari 6, TR-34510 Istanbul, Turkey
来源
WORLD JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 11卷 / 02期
关键词
Objective response rate; Tumor shrinkage; World Health Organization criteria; Response Evaluation Criteria in Solid Tumors; Immune Response Evaluation Criteria in Solid Tumors criteria; Early tumor shrinkage; Depth of response; Waterfall plot; Spider plot; Swimmer plot; METASTATIC COLORECTAL-CANCER; EARLY TUMOR SHRINKAGE; POSITRON-EMISSION-TOMOGRAPHY; IMMUNE-RELATED RESPONSE; OXALIPLATIN-BASED CHEMOTHERAPY; MODIFIED RECIST CRITERIA; SINGLE LARGEST LESION; SOLID TUMORS; LIVER METASTASES; PATHOLOGICAL RESPONSE;
D O I
10.5306/wjco.v11.i2.53
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor objective response rate (ORR) is an important parameter to demonstrate the efficacy of a treatment in oncology. The ORR is valuable for clinical decision making in routine practice and a significant end-point for reporting the results of clinical trials. World Health Organization and Response Evaluation Criteria in Solid Tumors (RECIST) are anatomic response criteria developed mainly for cytotoxic chemotherapy. These criteria are based on the visual assessment of tumor size in morphological images provided by computed tomography (CT) or magnetic resonance imaging. Anatomic response criteria may not be optimal for biologic agents, some disease sites, and some regional therapies. Consequently, modifications of RECIST, Choi criteria and Morphologic response criteria were developed based on the concept of the evaluation of viable tumors. Despite its limitations, RECIST v1.1 is validated in prospective studies, is widely accepted by regulatory agencies and has recently shown good performance for targeted cancer agents. Finally, some alternatives of RECIST were developed as immune-specific response criteria for checkpoint inhibitors. Immune RECIST criteria are based essentially on defining true progressive disease after a confirmatory imaging. Some graphical methods may be useful to show longitudinal change in the tumor burden over time. Tumor tissue is a tridimensional heterogenous mass, and tumor shrinkage is not always symmetrical; thus, metabolic response assessments using positron emission tomography (PET) or PET/CT may reflect the viability of cancer cells or functional changes evolving after anticancer treatments. The metabolic response can show the benefit of a treatment earlier than anatomic shrinkage, possibly preventing delays in drug approval. Computer-assisted automated volumetric assessments, quantitative multimodality imaging in radiology, new tracers in nuclear medicine and finally artificial intelligence have great potential in future evaluations.
引用
收藏
页码:53 / 73
页数:21
相关论文
共 50 条
  • [1] Biosimilars: Current situation and future expectations
    Forno, Guillermina
    Orti, Eduardo
    [J]. EUROPEAN JOURNAL OF RISK REGULATION, 2012, 3 (02) : 213 - 218
  • [2] Current status and future expectations of nanobodies in oncology trials
    De Pauw, Tessa
    De Mey, Lynn
    Debacker, Jens M.
    Raes, Geert
    Van Ginderachter, Jo A.
    De Groof, Timo W. M.
    Devoogdt, Nick
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2023, : 705 - 721
  • [3] Paediatric oncology in Europe: current situation and future directions
    Ruth Ladenstein
    [J]. memo - Magazine of European Medical Oncology, 2009, 2 (4) : 199 - 200
  • [4] Paediatric oncology in Europe: current situation and future directions
    Ladenstein, R.
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2009, 2 (04) : 199 - 200
  • [5] International evolution in AYA oncology: Current status and future expectations
    Ferrari, Andrea
    Barr, Ronald D.
    [J]. PEDIATRIC BLOOD & CANCER, 2017, 64 (09)
  • [6] Advance directives in dermato-oncology: The current situation and future prospects
    Velter, C.
    Cribier, B.
    Goldwasser, F.
    Vinant, P.
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2016, 143 (8-9): : 505 - 511
  • [7] Radiation oncology: Future needs and equipment. Current situation in Spain
    Palacios Eito, Amalia
    Espinosa Calvo, Maria
    Manas Rueda, Ana
    de las Heras, Manuel
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (08): : 478 - 485
  • [8] Radiation oncology: Future needs and equipment. Current situation in Spain
    Amalia Palacios Eito
    María Espinosa Calvo
    Ana Mañas Rueda
    Manuel de las Heras
    [J]. Clinical and Translational Oncology, 2008, 10 : 478 - 485
  • [9] THE ASSESSMENT OF ENTREPRENEURIAL PERSONALITY: THE CURRENT SITUATION AND FUTURE DIRECTIONS
    Suarez-Alvarez, Javier
    Pedrosa, Ignacio
    [J]. PAPELES DEL PSICOLOGO, 2016, 37 (01): : 62 - 68
  • [10] Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations
    Tronel, Claire
    Largeau, Berenger
    Ribeiro, Maria Joao Santiago
    Guilloteau, Denis
    Dupont, Anne-Claire
    Arlicot, Nicolas
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (04):